1. Home
  2. BXSL vs GKOS Comparison

BXSL vs GKOS Comparison

Compare BXSL & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Secured Lending Fund of Beneficial Interest

BXSL

Blackstone Secured Lending Fund of Beneficial Interest

HOLD

Current Price

$26.42

Market Cap

6.1B

Sector

Finance

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$121.95

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXSL
GKOS
Founded
2018
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
6.3B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
BXSL
GKOS
Price
$26.42
$121.95
Analyst Decision
Buy
Strong Buy
Analyst Count
8
14
Target Price
$29.13
$130.93
AVG Volume (30 Days)
1.8M
728.9K
Earning Date
02-25-2026
02-17-2026
Dividend Yield
11.54%
N/A
EPS Growth
N/A
N/A
EPS
2.66
N/A
Revenue
$1,413,784,000.00
$469,820,000.00
Revenue This Year
$9.05
$31.33
Revenue Next Year
$0.48
$24.01
P/E Ratio
$10.04
N/A
Revenue Growth
10.58
30.38
52 Week Low
$24.85
$73.16
52 Week High
$34.64
$163.71

Technical Indicators

Market Signals
Indicator
BXSL
GKOS
Relative Strength Index (RSI) 47.41 61.92
Support Level $25.90 $93.96
Resistance Level $26.94 $130.23
Average True Range (ATR) 0.56 5.21
MACD 0.05 0.81
Stochastic Oscillator 62.61 77.20

Price Performance

Historical Comparison
BXSL
GKOS

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: